182 related articles for article (PubMed ID: 27765901)
21. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression.
Ji Q; Liu X; Han Z; Zhou L; Sui H; Yan L; Jiang H; Ren J; Cai J; Li Q
BMC Cancer; 2015 Mar; 15():97. PubMed ID: 25884904
[TBL] [Abstract][Full Text] [Related]
22. Drug-resistant CXCR4-positive cells have the molecular characteristics of EMT in NSCLC.
Yin H; Wang Y; Chen W; Zhong S; Liu Z; Zhao J
Gene; 2016 Dec; 594(1):23-29. PubMed ID: 27581786
[TBL] [Abstract][Full Text] [Related]
23. Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2.
Ye Z; Yin S; Su Z; Bai M; Zhang H; Hei Z; Cai S
Oncotarget; 2016 Jun; 7(25):37524-37535. PubMed ID: 27229528
[TBL] [Abstract][Full Text] [Related]
24. Cisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2.
Xu G; Yu H; Shi X; Sun L; Zhou Q; Zheng D; Shi H; Li N; Zhang X; Shao G
BMC Pulm Med; 2014 Nov; 14():174. PubMed ID: 25380840
[TBL] [Abstract][Full Text] [Related]
25. Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells.
Circu M; Cardelli J; Barr MP; O'Byrne K; Mills G; El-Osta H
PLoS One; 2017; 12(9):e0184922. PubMed ID: 28945807
[TBL] [Abstract][Full Text] [Related]
26. Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor.
Zuco V; Cassinelli G; Cossa G; Gatti L; Favini E; Tortoreto M; Cominetti D; Scanziani E; Castiglioni V; Cincinelli R; Giannini G; Zunino F; Zaffaroni N; Lanzi C; Perego P
Biochem Pharmacol; 2015 Mar; 94(2):79-90. PubMed ID: 25600908
[TBL] [Abstract][Full Text] [Related]
27. Transglutaminase-2 induces N-cadherin expression in TGF-β1-induced epithelial mesenchymal transition via c-Jun-N-terminal kinase activation by protein phosphatase 2A down-regulation.
Park MK; You HJ; Lee HJ; Kang JH; Oh SH; Kim SY; Lee CH
Eur J Cancer; 2013 May; 49(7):1692-705. PubMed ID: 23290789
[TBL] [Abstract][Full Text] [Related]
28. Angiotensin-converting enzyme 2 attenuates the metastasis of non-small cell lung cancer through inhibition of epithelial-mesenchymal transition.
Qian YR; Guo Y; Wan HY; Fan L; Feng Y; Ni L; Xiang Y; Li QY
Oncol Rep; 2013 Jun; 29(6):2408-14. PubMed ID: 23545945
[TBL] [Abstract][Full Text] [Related]
29. Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling.
Wang ZL; Fan ZQ; Jiang HD; Qu JM
Carcinogenesis; 2013 Mar; 34(3):638-46. PubMed ID: 23172668
[TBL] [Abstract][Full Text] [Related]
30. FASN, ErbB2-mediated glycolysis is required for breast cancer cell migration.
Zhou L; Jiang S; Fu Q; Smith K; Tu K; Li H; Zhao Y
Oncol Rep; 2016 May; 35(5):2715-22. PubMed ID: 26936618
[TBL] [Abstract][Full Text] [Related]
31. IL-6 promotes growth and epithelial-mesenchymal transition of CD133+ cells of non-small cell lung cancer.
Lee SO; Yang X; Duan S; Tsai Y; Strojny LR; Keng P; Chen Y
Oncotarget; 2016 Feb; 7(6):6626-38. PubMed ID: 26675547
[TBL] [Abstract][Full Text] [Related]
32. Fatty acid synthase mediates the epithelial-mesenchymal transition of breast cancer cells.
Li J; Dong L; Wei D; Wang X; Zhang S; Li H
Int J Biol Sci; 2014; 10(2):171-80. PubMed ID: 24520215
[TBL] [Abstract][Full Text] [Related]
33. miR-15b regulates cisplatin resistance and metastasis by targeting PEBP4 in human lung adenocarcinoma cells.
Zhao Z; Zhang L; Yao Q; Tao Z
Cancer Gene Ther; 2015 Apr; 22(3):108-14. PubMed ID: 25721211
[TBL] [Abstract][Full Text] [Related]
34. Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer.
Shintani Y; Okimura A; Sato K; Nakagiri T; Kadota Y; Inoue M; Sawabata N; Minami M; Ikeda N; Kawahara K; Matsumoto T; Matsuura N; Ohta M; Okumura M
Ann Thorac Surg; 2011 Nov; 92(5):1794-804; discussion 1804. PubMed ID: 22051275
[TBL] [Abstract][Full Text] [Related]
35. The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model.
Papaevangelou E; Almeida GS; Box C; deSouza NM; Chung YL
Int J Cancer; 2018 Aug; 143(4):992-1002. PubMed ID: 29569717
[TBL] [Abstract][Full Text] [Related]
36. Confluence-dependent resistance to cisplatin in lung cancer cells is regulated by transforming growth factor-beta.
Yokokura S; Kanaji N; Tadokoro A; Yokokura S; Kadowaki N; Bandoh S
Exp Lung Res; 2016 May; 42(4):175-81. PubMed ID: 27116015
[TBL] [Abstract][Full Text] [Related]
37. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
[TBL] [Abstract][Full Text] [Related]
38. Epicatechin-3-gallate reverses TGF-β1-induced epithelial-to-mesenchymal transition and inhibits cell invasion and protease activities in human lung cancer cells.
Huang SF; Horng CT; Hsieh YS; Hsieh YH; Chu SC; Chen PN
Food Chem Toxicol; 2016 Aug; 94():1-10. PubMed ID: 27224248
[TBL] [Abstract][Full Text] [Related]
39. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R
Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770
[TBL] [Abstract][Full Text] [Related]
40. Atorvastatin partially inhibits the epithelial-mesenchymal transition in A549 cells induced by TGF-β1 by attenuating the upregulation of SphK1.
Fan Z; Jiang H; Wang Z; Qu J
Oncol Rep; 2016 Aug; 36(2):1016-22. PubMed ID: 27349500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
